Cancer Cell International

Cancer Cell International (commonly abbreviated as ''Cancer Cell Int.') is a fully open access journal of BioMed Central and Springer Nature. Founded in 2001, it publishes original research in cancer biology and cancer therapy, with a 2025 impact factor of 7.Cancer Cell International（常用缩写 Cancer Cell Int.）是 BMC 系列旗下的一份完全开放获取期刊，由 BioMed Central 与 Springer Nature 出版，2001 年创刊，刊载肿瘤生物学与肿瘤治疗领域的原创研究，2025 年影响因子为 7。^[1]

Scope

Genre: the journal publishes original research papers on the biological behaviour of tumour cells and on interventions directed at them. It runs no review section and is therefore a research journal rather than a review title.体裁定位：刊发原创研究论文，主题围绕肿瘤细胞本身的生物学行为以及针对肿瘤细胞的干预手段，不设综述专栏，因此属于研究刊而非综述刊。
Subject coverage: the journal covers cancer cell biology, tumour immunology, cancer metabolism, cancer stem cells, cellular signalling and apoptosis control, as well as mechanisms of drug resistance and targeting strategies in cancer therapy.收录领域：覆盖肿瘤细胞生物学、肿瘤免疫学、肿瘤代谢、肿瘤干细胞、细胞信号与凋亡调控，以及肿瘤治疗中的耐药机制与靶向策略。
Experimental models: the journal welcomes work based on cell culture models, organoids and xenograft models, as well as translational studies on human tumour samples that include corresponding functional validation.实验模型：欢迎以细胞培养模型、类器官、动物移植瘤模型为基础的研究，以及以人类肿瘤样本为基础并有相应功能验证的转化研究。
Open access and charges: the journal is fully open access and every article is free to read. An article processing charge applies to original research articles, and the submission system displays the current standard at the point of peer review.开放获取与费用：期刊为完全开放获取，全部文章均可免费阅读；发表原创研究论文需缴纳文章处理费，投稿系统会在送审环节显示具体标准。
Indexing and metrics: the journal is indexed in the Science Citation Index Expanded and ranks in the first quartile in the Oncology category, with a 2025 impact factor of 7, which places it among the fully open access titles with higher impact factors in that quartile.收录与指标：收录于科学引文索引扩展版，在肿瘤学类别中分区为第一区，2025 年影响因子为 7，属该分区中影响因子较高的完全开放获取刊物。
Position within the BMC portfolio: as part of the BMC family the journal follows that publisher's editorial conventions, including an author- and reader-centred editorial process, transparent peer-review policy, and the absence of charges beyond those levied on manuscripts.BMC 系列的定位：作为 BMC 品牌的一员，期刊遵循该系列的办刊规范，包括以作者与读者为中心的编辑流程、透明的同行评审政策，以及不向作者收取稿件处理之外的额外费用。^[2]

History

2001: the journal was founded and published by BioMed Central. It adopted a fully open access model from the outset, an unusual choice among the large publishing operations of the time.2001年：期刊创刊，由 BioMed Central 出版，创刊之初即采取完全开放获取模式，这在当时的大型出版体系中尚属少数做法。
The 2000s to the 2010s: the journal's standing grew steadily until it became one of the fully open access titles receiving a substantial volume of submissions in cancer cell biology. Its subject matter also widened from purely in-vitro mechanistic work to the tumour microenvironment and therapeutic response.2000年代至2010年代：期刊影响力稳步上升，逐步成为肿瘤细胞生物学方向上作者投稿量较大的完全开放获取刊物之一，稿件主题也从纯体外机制研究扩展到肿瘤微环境与治疗反应。
2020: BioMed Central completed a full consolidation of the BMC brand. The journal kept its title but was folded into the unified BMC publishing system, with its editorial and submission processes progressively merged. The publisher has been BioMed Central since the journal was founded2020年： BioMed Central 完成对 BMC 系列品牌的全面整合，期刊在保留原有刊名的前提下归入统一的 BMC 出版体系，编辑与投稿流程逐步并轨；出版方自创刊起始终为 BioMed Central，该机构于 2010 年被 Springer Science+Business Media 收购，其后随 Springer Nature 的合并延续至今。 that company was acquired by Springer Science+Business Media in 2010 and has since continued within Springer Nature.
Recent years: the impact factor has continued to rise, reaching 7 in 2025. Within the Oncology category the journal now sits firmly in the first quartile and is among the fully open access titles with the highest impact factors there.近年：期刊的影响因子持续上行，2025 年达到 7，在肿瘤学类别中稳居第一区，成为该分区中影响因子最高的完全开放获取刊物之一。^[3]

Editors

Editors-in-chief: the journal has two editors-in-chief. They are Yasumasa Kato, MedScD PhD of Obu University in Koriyama, Japan, and Andy Tao Yin Lau PhD of Shantou University Medical College in China. The two-editor arrangement ensures that both cancer cell biology and tumour immunology are properly represented.共同主编：期刊设两位共同主编，分别为日本郡山共存大学（Obu University）的 Yasumasa Kato 医学科学博士与中国汕头大学医学院的 Andy Tao Yin Lau 博士，双主编制使肿瘤细胞生物学与肿瘤免疫学两个方向同时有人把关。
Associate editors: there are sixty-seven associate editors, a notably large number for a journal of this kind. They cover cancer metabolism, apoptosis, DNA damage repair and immunotherapy, and are drawn from institutions in the United States, Italy, China, Germany, India, Japan, South Korea, the United Kingdom and Mexico.副主编：副编辑六十七位，规模之大在本类期刊中相当突出，分属肿瘤代谢、细胞凋亡、DNA 损伤修复与免疫治疗等方向，分属美国、意大利、中国、德国、印度、日本、韩国、英国与墨西哥等国机构。
Composition of the board: the associate editors are well balanced geographically, with clinicians and basic researchers sitting side by side. Among them are senior investigators at the University of Pennsylvania, Memorial Sloan Kettering Cancer Center, Johns Hopkins University and Stanford University. The journal's submissions therefore concentrate on experimental work.编委构成：副编辑名单按地域分布相当均衡，临床与基础研究者并列，其中不乏如宾夕法尼亚大学、纪念斯隆凯特琳癌症中心、约翰霍普金斯大学与史丹福大学等机构的资深研究者，刊物的稿源因此集中在实验研究。
Service commitment and ethics: the editors commit to returning a definite decision on every submission, with constructive comments as the guiding rule. Under BMC practice the judgement is made by the editorial team rather than by an outside referee. Manuscripts are lodged through the publisher's online submission system, which also handles plagiarism screening, ethics-declaration checks and collection of author contribution statements, and the journal sets out specific ethics requirements for studies involving human subjects or animals.服务承诺与伦理要求：期刊编辑部公开承诺对作者的来稿给予明确答复，评审意见以建设性为原则，BMC 系列的标准在于编辑团队而非外部审稿人对稿件作出判断；稿件通过出版方在线投稿系统递交，该系统同时承担查重、伦理声明核验与作者贡献声明的收集，期刊对涉及人类受试者或动物实验的稿件设有专门的伦理审查要求。^[4]

References